Stay consistent with lifestyle changes while working with your doctor to achieve your health goals
Competitive Landscape GLP-1 Weight Loss Drug Market Competitive Landscape: Novo Nordisk and Eli Lilly Duopoly, Oral GLP-1 Challengers, and Telehealth Platforms Reshape the Obesity Drug Market Through 2035 The GLP-1 Weight Loss Drug Market competitive landscape is defined by exceptional concentration at the approved drug tier where Novo Nordisk and Eli Lilly collectively control approximately 87% of global prescription obesity drug revenue combined with intense clinical development competition among more than 40 active GLP-1 pipeline programs
Furthermore, GLP-1RAs have been shown to attenuate microglial activation and improve memory-related behaviors
DPP-4 inhibitors also have a favorable cardiovascular safety profile [141]
This review summarizes updated research findings regarding the adverse effects of GLP-1 RAs, their mechanisms of action, and guidelines for clinical application
Pathologically elevated ICP can be reduced by nearly 50% in rats with intracranial hypertension treated with exenatide, with effects sustained over a week
